Olga Guryanova is an NIH-funded investigator with 15+ years of experience in translational cancer research. Her scientific career has been driven by a commitment to innovative studies into molecular mechanisms of chemotherapeutic resistance and rational strategies for cancer cell re-sensitization, with translational implications and a focus on precision oncology. After training at the Cleveland Clinic with Dr. Jeremy Rich, an expert in malignant brain tumors, she completed a postdoctoral fellowship at Memorial Sloan Kettering Cancer Center (MSKCC) under Dr. Ross Levine, a world-class authority in hematologic malignancies. Dr. Guryanova’s research has been published in top-tier journals such as Nature Medicine, Cancer Cell, and Clinical Cancer Research as a first and a senior author. She is currently an Assistant Professor and member of the University of Florida Health Cancer Center, where her laboratory is focused on delineating the mechanisms of the cross-talk between epigenetics and chromatin organization, and how these processes contribute to the development of myeloid malignancies such as acute myeloid leukemia (AML), resistance to therapies, and clonal evolution. Ultimately, Dr. Guryanova would like to harness this mechanistic understanding to develop improved therapeutic approaches for leukemia.